Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.
New York City
Friday, October 4 at 7:45 a.m. Eastern time (ET).
October 11, 2019
Once-daily oral Linzagolix doses of 75 mg and 100 mg without hormonal add-back therapy could lead to symptom relief of…Read more
October 9, 2019
Geneva, Switzerland and Boston, MA – October 9, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage…Read more
September 27, 2019
Geneva, Switzerland and Boston, MA – September 27, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical…Read more
May 8, 2019
May 9, 2018
March 2, 2020
November 11, 2019
October 17, 2019